# Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

> **NCT00542178** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 3472 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Hypoglycemic Agents
- **DRUG:** Standard glycemia control
- **DRUG:** Intensive BP treatment
- **DRUG:** Standard BP control
- **DRUG:** Fenofibrate
- **DRUG:** Simvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00542178
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 3472 (ACTUAL)
- **Last updated:** 2018-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542178, "Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00542178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*